Recently, repurposing bumetanide as an AD medication was proposed based on data that showed bumetanide “reversed” APOE genotype-dependent transcriptomic signatures in mouse and cell culture models.4 This finding was investigated in two EHR-based cohorts demonstrating that in individuals over 65 years of age, bumetanide exposure was associated with lower AD prevalence4. The gene discussed is APOE; the disease is Alzheimer disease.